European Journal of Molecular & Clinical Medicine

Abstract

Boosted therapy of immunization against SARS-CoV2 has already been certified to progress for humans all around the world. After having a long breakthrough of a pandemic, the physiological response of human cells is now presenting as omnipotent characters for their autoimmune criteria against a viral antigen, types, sub-types, strains, and modified strains. The molecular genesis is migrated and conducts with a different pattern of doses but specified in the same dosed to administer by injected protein derivatives. The viral epitopes and their surface protein are concerned with the activation of monoclonal antibodies by the artificial secondary immune response. The artificial immunogenetic is explored by analytical research of several trials of virologists from mid- August to December 2020. The ethical confirmation of molecular phenomena of antigenantibody interaction works in the same module and different manufacturing identity against SARS-CoV2. The accuracy of antigen-antibody titer is determined on the efficacy margin of an implemented vaccine in a mass population formulating the reports and
outcomes on boosted series of injections. In these circumstances, the conceptual models are required to study the SARS-CoV2 prone regions framed on the statistical alignment of the affected population during the pandemic.